The diagnostic features and therapeutic strategies for malignant paraganglioma in a patient: A case report

Gan L et al. Diagnosis and treatment of malignant paraganglioma

Lei Gan, Xu-Dong Shen, Yang Ren, Hong-Xia Cui, Zhi-Xiang Zhuang

Abstract

BACKGROUND
Paragangliomas and extra-adrenal pheochromocytomas are uncommon neuroendocrine tumors with ubiquitous distribution. Malignant paraganglioma is a relatively rare entity. We report the treatment and pathological characteristics of a patient with malignant paraganglioma, and summarize the latest advances in the treatment of malignant paraganglioma based on a literature review.

CASE SUMMARY
A 45-year-old Chinese woman presented to the hospital due to pain in the waist (right side) and right buttock, and was diagnosed as malignant paraganglioma after the placement of ureteral stent, implantation of ileus catheter, and transvaginal removal of the vaginal mass. After relief of intestinal obstruction, the patient received intravenous chemotherapy and peritoneal perfusion chemotherapy. Although her pelvic mass disease was stable, she developed multiple liver metastases and bone metastases. Due to the development of spinal cord compression, she underwent orthopedic surgery, followed by radiotherapy, and molecular targeted therapy with apatinib, but with poor disease control.
CONCLUSION
Clinical management of paraganglioma is challenging for endocrinologists and oncologists. Prospective studies are required to develop standardized therapeutic strategies for malignant paragangliomas.

Key Words: Malignant paraganglioma; Chemotherapy; Radiotherapy; Targeted therapy; Case report


Core Tip: Paragangliomas are widely distributed and have diverse clinical manifestations. Although most paragangliomas are benign, the malignancy is involved in approximately 10% of paragangliomas. The traditional treatment of malignant paragangliomas is surgery to the primary site. Surgery followed by adjuvant radiation is used less frequently, and chemotherapy is typically reserved for the distant disease. This study indicated the diagnostic features and therapeutic strategies of malignant paraganglioma. Therapeutic strategies for malignant paragangliomas are lacking. After the initial treatment, the patient’s progression-free survival reached 21 mo. Subsequently, the patient progressed and was treated again with chemoradiotherapy, surgery, and targeted therapy.

INTRODUCTION
Pheochromocytomas and paragangliomas (PPGLs) are rare catecholamine-secreting endocrine tumors. Paraganglioma, first reported by Felix Frankel in 1886[1], is a neuroendocrine tumor arising from the neural crest cells and may occur anywhere along the paraganglia of the autonomic nervous system[2-3]. PGL is characterized by
persistent hypertension and sympathetic activation. The main clinical features include hypertension, headache, hypermetabolism, hyperglycemia, and excessive sweating\(^4\). Approximately 10% of paragangliomas are malignant\(^5\) and are characterized by metastatic spread. The traditional treatment for malignant paragangliomas is surgical excision of the primary lesion. Surgery followed by adjuvant radiation is used less frequently, and chemotherapy is typically reserved for cases with distant metastasis\(^6\)\(^-\)\(^8\).

On immunohistochemical staining, paragangliomas generally exhibit positivity for neuron specific enolase (NSE), synaptophysin (Syn), and chromogranin A (CgA) within the chief cells, and S-100 and GFAP within the sustentacular cells\(^9\)\(^-\)\(^11\). Here we report the treatment of a middle-aged Chinese woman with malignant paraganglioma who was diagnosed based on immunohistochemical analyses, clinical symptoms, hematological examination, and imaging findings.

**CASE PRESENTATION**

*Chief complaints*

A 45-year-old Chinese woman presented with pain in right side of waist and right buttock, which has been present since April 2018.

*History of present illness*

She was experiencing pain extending from the right waist to the right buttock since April 2018. Initial physical examination and vital signs showed no significant abnormalities, and initial laboratory results were within the normal range.

*History of past illness*

Twenty-three years ago, the patient had a history of removal of a vaginal mass and a cesarean section. The previously removed vaginal mass was considered benign (not available for review). She was told that additional clinical or radiological follow-up was not necessary.
**Personal and family history**

There was no family history of specific genetic or infectious diseases.

**Physical examination**

Physical examination revealed tenderness over the kidney region on percussion. Her vital parameters were: temperature, 36.5 °C; pulse rate, 75 beats/min; blood pressure, 135/88 mmHg.

**Laboratory examinations**

The laboratory test findings were unremarkable. Biochemical tests showed normal levels of glutamic oxaloacetic transaminase, glutamic pyruvic transaminase, total bilirubin, direct bilirubin, indirect bilirubin. Her electrolyte profile and renal function tests were normal. Tumor markers such as α-fetoprotein, carcinoembryonic antigen, and carbohydrate antigen 199 were negative, and there was no evidence of hepatitis A, B, C or E virus infection. Her blood pressure increased during hospitalization, and auxiliary examination showed increased levels of 24-h urine vanillylmandelic acid (VMA) (22.40 mg/24 h) and urine methoxynorepinephrine (NMN) levels (3880 μg/24 h).

**Pathological examination**

Ureteral stent implantation and laparoscopic pelvic mass biopsy were performed on May 17, 2018. Routine postoperative pathology showed that the cystic wall-like tissues of the pelvic mass were covered with squamous epithelium and other nerve tissues, suggesting the possibility of mature cystic teratoma. The patient recovered well after the operation and was referred to the gynecology department for further treatment. On December 6, 2018, the patient underwent transvaginal resection of the vaginal mass and laparoscopic release of pelvic adhesions. Routine postoperative pathology showed that the vaginal wall nodule was a malignant tumor, pending further diagnosis by the immunopathology. After the surgery, the patient developed abdominal distension and
failed to pass flatus. X-ray indicated ileus and an ileus catheter was placed. However, the abdominal distension continued to aggravate. On December 24, 2018, CT-guided peritoneal puncture and drainage were performed; cytological examination revealed no tumor cells in the ascites fluid. The immunopathological examination of the vaginal mass was consistent with malignant paraganglioma. On immunohistochemical analysis, the tumor cells expressed S100 (+), Syn (+), CgA (+), CD56 (+), CD10 (-), Ki67 (+, 5%) and CK (-).

**Imaging examinations**
At the onset of symptoms in early April 2018, the patient had undergone B-ultrasonography at a local hospital, which showed right-sided hydronephrosis accompanied by distension of the right upper ureter and hypoechoic pelvic cavity on the right side. On admission at our hospital, enhanced computed tomography (CT) showed right hydronephrosis, right lower ureter mass, and right-sided vaginal mass (Figure 1).

**FINAL DIAGNOSIS**
The final pathological diagnosis after biopsy was malignant paraganglioma (Figure 2).

**TREATMENT**
After the patient was relieved of intestinal obstruction, she received 2 cycles of liposome doxorubicin (25 mg/m²) intravenous chemotherapy combined with cisplatin (75 mg/m²) intraperitoneal infusion chemotherapy, which resulted in significant reduction in the pelvic effusion (Figure 3). The patient received a total of 7 cycles of liposome doxorubicin (25 mg/m²) in combination with cisplatin (75 mg/m²) intravenous chemotherapy until June 2019.

**OUTCOME AND FOLLOW-UP**
After completion of chemotherapy, the patient was followed up regularly, and the patient's symptoms were stable until April 2020 (Figure 4). During the diagnosis, treatment and follow-up of this patient, we simultaneously analyzed her blood tumor biomarkers. There are no specific tumor biomarkers for malignant paraganglioma, but on follow-up examinations, we found a gradual decrease in the ferritin content of this patient following the effective treatment. This indicated that ferritin content is a potential evaluation index of therapeutic efficacy in these patients (Figure 5).

In September 2020, the patient came to our hospital for re-examination. Enhanced CT scan indicated an increase in the size of the right pelvic mass (Figure 6A). After comprehensive evaluation, the patient's disease was classified as progressive. Palliative radiotherapy was performed for the right pelvic mass (total dose 50 Gy administered in 25 sessions; 2 Gy per fraction). During the radiotherapy, two cycles of albumin-bound paclitaxel (260 mg/m²) in combination with nedaplatin (75 mg/m²) were simultaneously administered. After the radiotherapy, two cycles of intravenous chemotherapy with albumin-bound paclitaxel (260 mg/m²) combined with nedaplatin (75 mg/m²) were continued until December 2020. Repeat evaluation of the patient in March 2021, revealed multiple liver metastasis on enhanced CT scan, and the patient's disease was classified as progressive once more (Figure 6B).

After one month, the patient complained of discomfort in neck and left shoulder, and numbness in left upper limb. Neck and thoracic enhanced magnetic resonance imaging (MRI) showed multiple lesions in the cervical and thoracic vertebral bodies, considered as tumor metastasis. MRI also showed narrowing of the C6 vertebral body (Figure 7A). Enhanced CT showed further increase in the liver metastatic lesions (Figure 7B). In order to relieve the patient's spinal cord compression, anterior jugular tumor resection and iliac bone graft fusion and internal fixation were performed under general anesthesia by the orthopedic surgeon on May 18, 2021. Immunohistochemical analysis of the excised jugular tumor was consistent with bone metastasis of malignant paraganglioma (Figure 7C). In the follow-up process of the patient, the results of the patient's tumor biomarkers were shown in Figure 8. One month after the surgery, the
patient received palliative radiotherapy for bone metastases. Finally, the patient was initiated on molecular targeted therapy with apatinib.

**DISCUSSION**

Paragangliomas are defined as neuroendocrine tumors which may or may not produce catecholamines. Catecholamines such as dopamine, norepinephrine, and epinephrine are a class of neurotransmitters\[^{12}\]. The most common symptoms of catecholamine excess are hypertension, tachycardia, headache, pallor, sweating, and anxiety\[^{13, 14}\]. Pheochromocytomas/paragangliomas originate from chromaffin cells in the neural crest. Chromaffin cells are widely distributed in the adrenal medulla, sympathetic ganglia, and parasympathetic ganglia, and form Luckerkanal body which gradually atrophies in the adulthood in the para-aorta and the root of the inferior mesenteric artery. Paragangliomas were mostly believed to be undegenerated chromaffin tissues. Paragangliomas are widely distributed and have more diverse clinical manifestations than pheochromocytomas. In addition to the symptoms associated with excessive catecholamine secretion, local symptoms caused by tumor invasion may provide clues to the discovery of adrenal mass. Lesions in the retroperitoneal space may cause abdominal pain and/or lower back pain and constipation. Moreover, the mass may be palpable on physical examination. The common manifestations of paraganglioma include a series of sympathetic hyperactivity-related symptoms (such as paroxysmal hypertension and metabolic disorders), which are mainly attributable to the increase in blood catecholamine levels. Plasma and urine metanephrines and 24-h VMA levels may also increase. The first symptom of our patient was right-sided pain in the waist and hip. During hospitalization, her blood pressure increased and auxiliary examination revealed elevated 24-h urine VMA and urine NMN levels.

However, early diagnosis of malignant paraganglioma is difficult; moreover, pathological distinction between benign and malignant is challenging. Currently, the most reliable evidence for the determination of malignant lesions is the occurrence of vascular tumor emboli, local infiltration or lymph node involvement, and
hematogenous metastasis (such as bone metastasis, liver metastasis, lung metastasis). The cytologic diagnosis of paraganglioma can be challenging because of its rarity, wide anatomic distribution, and variable cytomorphological features. On immunohistochemical staining, malignant paraganglioma typically stain positive for CgA, NSE, vimentin, and S100, and negative for AE1/AE3. In the present case, immunohistochemical examination of the jugular tumor specimen showed high protein expression of S100, CgA, and Syn in the tumor cells. The best treatment of paraganglioma is complete surgical resection, but is challenging in case of local invasion and systemic spread of disease. Radiation therapy > 40 Gy typically achieves local tumor control and symptom relief\textsuperscript{[15-17]}. Systemic chemotherapy is indicated in cases of unresectable and progressive PGL, especially in patients with a high tumor burden and rapid progression. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine is optional\textsuperscript{[18,19]}. While no prospective clinical trials have evaluated its use, cardiovascular disease (CVD) has been shown to benefit 37% of PGL patients. CVD stops tumor growth, improves symptoms of catecholamine excess, and perhaps, prolongs survival\textsuperscript{[20,21]}. Tyrosine kinase inhibitors, such as sunitinib, as an additional option\textsuperscript{[22,23]}, have shown clinical benefit in 47% of patients with progressive PGL, demonstrating a poor median progression-free survival (PFS) of 4.1 mo\textsuperscript{[23]}. The efficacy of cytotoxic T-lymphocyte-associated antigen 4 and programmed death 1 immune checkpoint inhibitors ipilimumab, nivolumab, and pembrolizumab for treatment of metastatic PPGL is under investigation in phase II clinical trials.

There is a lack of standardized therapeutic strategies for malignant paragangliomas. Targeted radionuclide therapies using \textsuperscript{131}I-metaiodobenzylguanidine (\textsuperscript{131}I-MIBG) and peptide receptor radionuclide therapy (\textsuperscript{177}Lu or \textsuperscript{90}Y) are viable therapeutic options in the management of metastatic/inoperable pheochromocytoma/paraganglioma. Recently, high-specific-activity-\textsuperscript{131}I-MIBG therapy was approved by the FDA and both \textsuperscript{177}Lu-DOTATATE and \textsuperscript{131}I-MIBG therapy have been recommended by the National Comprehensive Cancer Network guidelines for the treatment of metastatic pheochromocytoma/paraganglioma. After \textsuperscript{131}I-MIBG treatment, the reported PFS was
Metastatic pheochromocytomas and paragangliomas have been shown to exhibit increased angiogenesis and expression of VEGF and PDGF-β receptors. A phase II study evaluated the antitumor activity of another tyrosine kinase receptor inhibitor, pazopanib, in MPPG by measuring the tumor response rate; of the six patients recruited to the study, two exhibited partial response. A phase II study of cabozantinib is currently recruiting patients with MPPG. The primary endpoint is to estimate objective response rate. An open-label phase II study of pembrolizumab in patients with MPPG has recently been activated. Other potential therapeutic targets such as mammalian target of rapamycin inhibitors, ATR inhibitors, and Wnt antagonists have been explored in clinical trials for patients with MPPG.

Because our patient had a large amount of abdominal and pelvic effusion, peritoneal puncture and drainage were performed, and peritoneal perfusion chemotherapy with cisplatin and intravenous chemotherapy with doxorubicin liposomes were administered. After two cycles of chemotherapy, there was significant reduction in abdominal and pelvic effusion. Several molecular targeted therapies, a novel radiopharmaceutical medication that targets the catecholamine transporter, and immunotherapy are under evaluation for the treatment of patients with malignant PPGs. Doxorubicin (DOX) is the most effective chemotherapeutic drug developed against a broad range of cancers such as solid tumors, leukemias, and lymphomas. Conventional DOX-induced cardiotoxicity has limited its use. FDA-approved drugs such as non-pegylated liposomal (Myocet®) and pegylated liposomal (Doxil®) formulations have no doubt shown comparatively reduced cardiotoxicity, but have raised new toxicity issues. The entrapment of doxorubicin in biocompatible, biodegradable, and safe nano delivery systems can prevent its degradation in circulation, minimize its toxicity with increased half-life, and enhance its pharmacokinetic profile leading to improved patient compliance. In addition, nano delivery systems can actively and passively target the tumor resulting in increased therapeutic index and decreased side effects of drug. In our case report, the patient
accepted chemotherapy combined with the pegylated liposomal doxorubicin and cisplatin 7 cycles until June 2019.

Our patient showed good therapeutic response after the initial treatment with 7 cycles of chemotherapy with cisplatin combined with doxorubicin liposomes, and the PFS reached 21 mo. However, after the first chemotherapy, the patient did not accept maintenance treatment, which led to disease progression. Subsequently, she opted for chemotherapy again combined with local radiotherapy. The patient received 4 cycles of palliative chemotherapy consisting of albumin-bound paclitaxel (260 mg/m²) combined with nedaplatin (75 mg/m²) totally. Although her pelvic mass disease was stable, she developed multiple metastatic lesions such as liver metastases and bone metastases, and subsequent targeted drug therapy with apatinib for almost 3 mo could not control the disease well. Surgery is the only cure for PCC/PGL; however, there is limited biochemical and tumor control of metastatic disease with treatments, including ¹³¹I-MIBG, chemotherapy, and radiation[26]. The poor characterization of the histological behavior and natural history of the disease makes clinical management of paraganglioma a great challenge for endocrinologists and oncologists. Prospective studies are required to develop standardized therapeutic strategies.

CONCLUSION
After the initial treatment, the patient’s PFS was 21 mo. During follow-up, enhanced CT scan showed enlargement of that right-sided pelvic mass, for which radiotherapy and chemotherapy were administered. Repeat imaging evaluation revealed bone metastases and liver metastases. Due to the development of spinal cord compression, she underwent orthopedic surgery, followed by radiotherapy and molecular targeted therapy with apatinib. The clinical management of paraganglioma is challenging. Management strategies for malignant paragangliomas include a combination of surgical resection, drug therapy to control symptoms of catecholamine overdose (metyrosine), radionuclide therapy (¹³¹I-MIBG or somatostatin analogue), chemotherapy (cyclophosphamide, vincristine combined with dacarbazine), and external irradiation
therapy. Most of these treatments are palliative, and targeted gene therapy based on tumor gene expression needs to be further explored. Prospective studies are required to develop more refined therapeutic strategies for paragangliomas.
<table>
<thead>
<tr>
<th></th>
<th>Source</th>
<th>Reference</th>
<th>Words</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td><a href="http://www.wjgnet.com">www.wjgnet.com</a></td>
<td>Oksana Hamidi. &quot;Metastatic pheochromocytoma and paraganglioma&quot;, Current Opinion in Endocrinology &amp; Diabetes and Obesity, 2019</td>
<td>40</td>
<td>1%</td>
</tr>
<tr>
<td>4</td>
<td>biomedres.us</td>
<td>Oksana Hamidi. &quot;Metastatic pheochromocytoma and paraganglioma&quot;, Current Opinion in Endocrinology &amp; Diabetes and Obesity, 2019</td>
<td>33</td>
<td>1%</td>
</tr>
<tr>
<td></td>
<td>Title</td>
<td>Author(s)</td>
<td>Journal/Website</td>
<td>Word Count</td>
</tr>
<tr>
<td>---</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>8</td>
<td>Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas</td>
<td>Madhav Prasad Yadav, Sanjana Ballal, Chandrasekhar Bal.</td>
<td>EJNMMI Research, 2019</td>
<td>30 words</td>
</tr>
<tr>
<td>9</td>
<td>Malignant head and neck paragangliomas: Treatment efficacy and prognostic indicators</td>
<td>Sethi, Roshan V., Rosh K.V. Sethi, Marc W. Herr, and Daniel G. Deschler.</td>
<td>American Journal of Otolaryngology, 2013.</td>
<td>26 words</td>
</tr>
<tr>
<td>10</td>
<td>Pheochromocytoma and Paraganglioma</td>
<td>Lauren Fishbein.</td>
<td>Hematology/Oncology Clinics of North America, 2016</td>
<td>23 words</td>
</tr>
<tr>
<td>11</td>
<td>Paraganglioma: Cytomorphologic features, radiologic and clinical findings in 12 cases</td>
<td>J. Judd Fite, Zahra Maleki.</td>
<td>Diagnostic Cytopathology, 2018</td>
<td>19 words</td>
</tr>
<tr>
<td>12</td>
<td>Pheochromocytoma</td>
<td>Anil Bhansali.</td>
<td>The Endocrinologist, 01/2009</td>
<td>15 words</td>
</tr>
<tr>
<td>13</td>
<td></td>
<td></td>
<td>f6publishing.blob.core.windows.net.net</td>
<td>25 words</td>
</tr>
<tr>
<td>14</td>
<td></td>
<td></td>
<td>pubmed.ncbi.nlm.nih.gov</td>
<td>26 words</td>
</tr>
<tr>
<td>15</td>
<td></td>
<td></td>
<td>josr-Online.biomedcentral.com</td>
<td>12 words</td>
</tr>
<tr>
<td></td>
<td><a href="http://www.frontiersin.org">www.frontiersin.org</a></td>
<td>17</td>
<td>Internet</td>
<td>11 words — &lt; 1%</td>
</tr>
<tr>
<td>---</td>
<td>---------------------</td>
<td>----</td>
<td>----------</td>
<td>----------------</td>
</tr>
<tr>
<td>18</td>
<td><a href="http://www.lawinst-spb.ru">www.lawinst-spb.ru</a></td>
<td>18</td>
<td>Internet</td>
<td>11 words — &lt; 1%</td>
</tr>
<tr>
<td>19</td>
<td><a href="http://www.nwpii.com">www.nwpii.com</a></td>
<td>19</td>
<td>Internet</td>
<td>11 words — &lt; 1%</td>
</tr>
</tbody>
</table>

**Exclude Quotes**: ON  
**Exclude Bibliography**: ON  
**Exclude Sources**: < 10 WORDS  
**Exclude Matches**: < 10 WORDS